Recombinant Human CD40 Protein, C-His-tagged

• Cat.No.: CD40-195H
• Product Overview: Recombinant Human CD40 Protein with C-His tag was expressed in E. coli.

Specification

• Description: CD40, also known as tumor necrosis factor receptor superfamily member 5 (TNFRSF5), is a type I transmembrane protein expressed on the surface of B cells and professional antigen-presenting cells of the immune system, as well as on several non-hematopoietic cell types and cancers. CD40 interacts with CD40 ligand (CD40L/TNFSF5), which is expressed primarily on activated T cells but has also been reported on blood platelets, mast cells, basophils, NK cells, and B cells. Upon engagement with CD40L, CD40 signals through TNF receptor associated factors and MAP kinase signaling pathways, resulting in a wide variety of immune and inflammatory responses, including dendritic cell activation and cross-presentation, T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The CD40/CD40L axis is essential for the initiation and progression of cellular and humoral adaptive immunity, and is an important area of interest in the study of tumor immunology, neurodegenerative diseases, vascular diseases, and inflammatory disorders.
• Source: E. coli
• Species: Human
• Tag: His
• Molecular Mass: ~19 kDa
• AA Sequence: EPPTACREKQYLINSQCCSLCQPGQ KLVSDCTEFTETECLPCGESEFLDT WNRETHCHQHKYCDPNLGLRVQQKG TSETDTICTCEEGWHCTSEACESCV LHRSCSPGFGVKQIATGVSDTICEP CPVGFFSNVSSAFEKCHPWTSCETK DLVVQQAGTNKTDVVCGPQDRLR
• Purity: Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE).
• Notes: For research use only, not for use in diagnostic procedure.
• Storage: Store at 4 centigrade short term. Aliquot and store at -20 centigrade long term. Avoid freeze-thaw cycles.
• Concentration: ≥0.5 mg/mL
• Storage Buffer: PBS, 4M Urea, pH7.4

Gene Information

• Gene Name: CD40 CD40 molecule, TNF receptor superfamily member 5 [ Homo sapiens (human) ]
• Official Symbol: CD40
• Synonyms: CD40; CD40 molecule, TNF receptor superfamily member 5; TNFRSF5, tumor necrosis factor receptor superfamily, member 5; tumor necrosis factor receptor superfamily member 5; Bp50; p50; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily, member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CDW40; TNFRSF5; MGC9013
• Gene ID: 958
• mRNA Refseq: NM_001250
• Protein Refseq: NP_001241
• MIM: 109535
• UniProt ID: P25942

Reviews

10/28/2021

Its utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.

08/11/2021

The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.

10/07/2018

CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.

Q&As

Can CD40-targeted therapies be used in the treatment of infectious diseases?

CD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.

Are there any approved drugs targeting CD40 for clinical use?

As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.

Can CD40-targeted therapies be used in combination with other cancer treatments?

Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.

What are the potential side effects of CD40-targeted therapies in cancer treatment?

Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.

Are there ongoing clinical trials exploring CD40-targeted therapies for atherosclerosis?

Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.